Price Change to Note: Time to Reconsider Selecta Biosciences Inc After Reaching 52-Week High?

Price Change to Note: Time to Reconsider Selecta Biosciences Inc After Reaching 52 Week High?

The stock of Selecta Biosciences Inc (NASDAQ:SELB) hit a new 52-week high and has $27.64 target or 5.00% above today’s $26.32 share price. The 7 months bullish chart indicates low risk for the $488.74M company. The 1-year high was reported on Nov, 28 by If the $27.64 price target is reached, the company will be worth $24.44M more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock. The stock decreased 0.04% or $0.01 during the last trading session, hitting $26.32. About 21,580 shares traded hands or 5.64% up from the average. Selecta Biosciences Inc (NASDAQ:SELB) has risen 6.00% since October 29, 2016 and is uptrending. It has underperformed by 0.01% the S&P500.

Analysts await Selecta Biosciences Inc (NASDAQ:SELB) to report earnings on February, 9. After $-0.43 actual EPS reported by Selecta Biosciences Inc for the previous quarter, Wall Street now forecasts 18.60% negative EPS growth.

According to Zacks Investment Research, “Selecta Biosciences, Inc. is a biopharmaceutical company which develops targeted immunotherapies and vaccines. Its product pipelineincludes gene therapy, food allergy, malaria; SEL-212, which is a therapeutic enzyme indicated for refractory gout; SEL-070, which is indicated for smoking cessation and relapse prevention; SEL-701, which is indicated for the treatment of human papillomavirus associated cancer and SEL-212 consists of SVP-Rapamycin co-administered with pegsiticase, its pegylated uricase. Selecta Biosciences, Inc. is based in Watertown, United States.”

More notable recent Selecta Biosciences Inc (NASDAQ:SELB) news were published by: which released: “/quotes/zigman/3870025/realtime” on May 26, 2016, also with their article: “Selecta Biosciences Announces Pricing of Initial Public Offering” published on June 22, 2016, published: “Selecta Biosciences Appoints Timothy C. Barabe to Board of Directors” on August 01, 2016. More interesting news about Selecta Biosciences Inc (NASDAQ:SELB) were released by: and their article: “Selecta Biosciences IPO: Consider A Modest Allocation” published on June 21, 2016 as well as‘s news article titled: “Selecta Biosciences Receives Exclusive Rights to Peanut Allergy and Celiac …” with publication date: November 10, 2016.

SELB Company Profile

Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Firm uses synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Firm operates in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases segment. The Company’s SVP technology encapsulates an immunomodulator in biodegradable nanoparticles to induce antigen-specific immune tolerance to mitigate the formation of anti-drug antibodies (ADA) in response to life-sustaining biologic drugs. The Company’s SVP technology has a range of applications to both manage biologic drugs and enable therapies. The Firm offers its product candidates in various programs, including SVP for immune tolerance and SVP for immune stimulation. The Company’s SVP for immune tolerance program includes Refractory and chronic tophaceous gout (SEL-212), Gene therapy for an autosomal recessive metabolic (ARM) disorder and Gene therapy for an X-linked metabolic (XLM) disorder. The Company’s SVP for immune stimulation includes Smoking cessation and relapse prevention (SEL-070), and human papillomavirus (HPV)-associated cancer (SEL-701). The Company’s antigen-specific SVP tolerance programs utilize SVP-Rapamycin, its biodegradable nanoparticle encapsulating the immunomodulator rapamycin. Rapamycin is a molecule approved for the prevention of organ rejection in kidney transplant patients. The Company’s SVP immune stimulation programs are designed to encapsulate an antigen and a toll-like receptor (TLR) agonist.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment